We are live on ! Find out more
RARE icon

Ultragenyx Pharmaceutical
RARE

100 hedge funds and large institutions have $1.23B invested in Ultragenyx Pharmaceutical in 2014 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 39 increasing their positions, 23 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

70% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 23

11% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 18

0% more funds holding

Funds holding: 100 → 100 (0)

14% less call options, than puts

Call options by funds: $342K | Put options by funds: $399K

18% less capital invested

Capital invested by funds: $1.5B → $1.23B (-$271M)

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

Holders
100
Holders Change
–
Holders Change %
0%
% of All Funds
2.67%
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
20
Increased
39
Reduced
23
Closed
18
Calls
$342K
Puts
$399K
Net Calls
-$57K
Net Calls Change
-$1.98M

Top Buyers

Rank Fund Capital Flow
1
BFA
BlackRock Fund Advisors
California
+$18.4M
2
Millennium Management
Millennium Management
New York
+$13.9M
3
Wellington Management Group
Wellington Management Group
Massachusetts
+$13.4M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$10M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$8.58M

Top Sellers

Rank Fund Capital Flow
1
TGHSA
TPG Group Holdings (SBS) Advisors
Texas
-$22.9M
2
CWAM
Columbia Wanger Asset Management
Illinois
-$21.1M
3
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$6.88M
4
GC
Guggenheim Capital
Illinois
-$3.79M
5
DCM
Driehaus Capital Management
Illinois
-$3.46M
Name Holding Trade Value Shares
Change 		Change in
Stake
JP Morgan Chase
26
JP Morgan Chase
New York
$8.83M +$265K +5,793 +3%
BBA
27
Baker Bros. Advisors
New York
$6.58M – – –
CI
28
Cowen Inc
New York
$6.56M +$22.9K +500 +0.3%
WMSA
29
Weiss Multi-Strategy Advisers
New York
$6.21M – – –
Geode Capital Management
30
Geode Capital Management
Massachusetts
$5.39M -$105K -2,292 -2%
CAM
31
Cormorant Asset Management
Massachusetts
$5.27M – – –
EA
32
Emerald Advisers
Pennsylvania
$5.14M +$3.41M +74,480 +174%
OM
33
Opaleye Management
Massachusetts
$4.66M +$971K +21,200 +25%
Northern Trust
34
Northern Trust
Illinois
$4.57M -$21.3K -465 -0.4%
BG
35
BlackRock Group
United Kingdom
$4.45M +$112K +2,445 +2%
EMFAT
36
Emerald Mutual Fund Advisers Trust
Pennsylvania
$4.08M +$2.35M +51,259 +122%
Brown Advisory
37
Brown Advisory
Maryland
$3.71M +$2.97M +64,728 +328%
LCP
38
Lamond Capital Partners
California
$3.42M +$3.57M +77,940 New
FAM
39
Fred Alger Management
New York
$3.32M +$3.46M +75,595 New
California Public Employees Retirement System
40
California Public Employees Retirement System
California
$3.18M +$1.97M +43,025 +349%
RSCM
41
Rock Springs Capital Management
Maryland
$3.12M +$160K +3,500 +5%
Morgan Stanley
42
Morgan Stanley
New York
$2.95M -$102K -2,219 -3%
Bank of New York Mellon
43
Bank of New York Mellon
New York
$2.85M -$1.25M -27,334 -30%
PI
44
Putnam Investments
Massachusetts
$2.84M – – –
Axa
45
Axa
France
$2.73M +$9.12K +199 +0.3%
CCM
46
Cupps Capital Management
Illinois
$2.49M -$2.53M -55,171 -49%
NI
47
Numeric Investors
Massachusetts
$2.47M +$2.58M +56,382 New
NFA
48
Nationwide Fund Advisors
Ohio
$2.31M +$282K +6,152 +13%
EAM
49
Eventide Asset Management
Massachusetts
$2.31M – – –
IHM
50
Iguana Healthcare Management
New York
$2.19M -$344K -7,500 -13%
1
2
3 4 5

RARE Hedge Fund Activity: Q4 2014 in Review

100 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q4 2014, worth a combined $1.23B — down 18% from $1.5B a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new RARE positions and 18 closed out — a net gain of 2 holders — while 39 added to existing stakes and 23 trimmed.

The largest buyer was BlackRock Fund Advisors, adding an estimated $18.4M. The largest seller was TPG Group Holdings (SBS) Advisors, cutting an estimated $22.9M.

  • 100 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q4 2014, unchanged from Q3 2014.
  • Funds reported $1.23B of Ultragenyx Pharmaceutical stock for Q4 2014, down 18% quarter-over-quarter.
  • 20 funds opened new Ultragenyx Pharmaceutical positions in Q4 2014 and 18 closed out, a net change of +2 holders.
  • The largest Ultragenyx Pharmaceutical buyer in Q4 2014 was BlackRock Fund Advisors, an estimated $18.4M added.
  • The largest Ultragenyx Pharmaceutical seller in Q4 2014 was TPG Group Holdings (SBS) Advisors, an estimated $22.9M sold.

Based on aggregated 13F filings for Q4 2014.